Indenture Agreements in the Biotechnology Industry

292 Contracts & Agreements
Browse by Company
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Fourth Supplemental Indenture between Biogen Inc. and U.S. Bank Trust Company, N.A. (May 12, 2025)
Indenture Agreements
Biogen Inc.
Biotechnology
DE
2025
First Supplemental Indenture to 1.500% Convertible Senior Subordinated Notes Due 2026 between Coherus BioSciences, Inc. and U.S. Bank Trust Company, N.A.
Indenture Agreements
Coherus BioSciences, Inc.
Biotechnology
NY
2025
Indenture for 2.00% Convertible Senior Notes due 2030 between Dynavax Technologies Corporation and U.S. Bank Trust Company, N.A.
Indenture Agreements
DYNAVAX TECHNOLOGIES CORP
Biotechnology
DE
2025
Indenture for 1.75% Convertible Senior Notes due 2031 between BridgeBio Pharma, Inc. and U.S. Bank Trust Company, N.A.
Indenture Agreements
BridgeBio Pharma, Inc.
Biotechnology
NY
2025
AbbVie Inc. Supplemental Indenture No. 11 for $4 Billion Senior Notes (2028–2055) with U.S. Bank Trust Company
Indenture Agreements
AbbVie Inc.
Biotechnology
NY
2025
First Supplemental Indenture to 7.00% Convertible Senior Notes due 2029 between Avid Bioservices, Inc. and U.S. Bank Trust Company, N.A.
Indenture Agreements
Avid Bioservices, Inc.
Biotechnology
NY
2025
First Supplemental Indenture to 7.00% Convertible Senior Notes due 2029 between Avid Bioservices, Inc. and U.S. Bank Trust Company, N.A.
Indenture Agreements
Avid Bioservices, Inc.
Biotechnology
NY
2025
Indenture for 5.75% Convertible Senior Subordinated Notes due 2030 between Esperion Therapeutics, Inc. and U.S. Bank Trust Company, N.A.
Indenture Agreements
Esperion Therapeutics, Inc.
Biotechnology
DE
2024
Tenth Supplemental Indenture to Indenture Dated March 30, 2011 between Gilead Sciences, Inc. and Computershare Trust Company, N.A. (as Trustee)
Indenture Agreements
Gilead Sciences
Biotechnology
NY
2024
First Supplemental Indenture to 3.875% Senior Unsecured Notes Due 2028—Emergent BioSolutions Inc. and U.S. Bank Trust Company, N.A.
Indenture Agreements
Emergent BioSolutions Inc.
Biotechnology
NY
2024
Amended and Restated Indenture for 11.00% / 13.00% Convertible Senior Secured Notes due 2028 among Biora Therapeutics, Inc., Guarantors, and GLAS Trust Company LLC
Indenture Agreements
PROGENITY, INC.
Biotechnology
NY
2024
First Supplemental Indenture to 2.50% Convertible Senior Notes Due 2027 between Cerevel Therapeutics Holdings, Inc. and U.S. Bank Trust Company, N.A.
Indenture Agreements
ARYA Sciences Acquisition Corp II
Biotechnology
2024
Fifth Supplemental Indenture to Indenture for 1.75% Convertible Senior Notes due 2031 between Exact Sciences Corporation and U.S. Bank Trust Company, N.A.
Indenture Agreements
EXACT SCIENCES CORP
Biotechnology
DE
2024
Second Supplemental Indenture between Biora Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A. (March 12, 2024)
Indenture Agreements
PROGENITY, INC.
Biotechnology
NY
2024
First Supplemental Indenture to 7.25% Convertible Senior Notes Due 2025 – Biora Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A.
Indenture Agreements
PROGENITY, INC.
Biotechnology
NY
2024
Indenture Agreement for 7.00% Convertible Senior Notes due 2029 between Avid Bioservices, Inc. and U.S. Bank Trust Company, N.A.
Indenture Agreements
Avid Bioservices, Inc.
Biotechnology
DE
2024
Supplemental Indenture to 11.00% / 13.00% Convertible Senior Notes Due 2028 between Biora Therapeutics, Inc. and GLAS Trust Company LLC
Indenture Agreements
PROGENITY, INC.
Biotechnology
NY
2024
AbbVie Inc. Supplemental Indenture No. 10 for Senior Notes Due 2027–2064 with U.S. Bank Trust Company
Indenture Agreements
AbbVie Inc.
Biotechnology
NY
2024
Indenture for 3.75% Convertible Senior Notes due 2029 between OPKO Health, Inc. and U.S. Bank Trust Company, N.A.
Indenture Agreements
Opko Health, Inc.
Biotechnology
DE
2024
Indenture for 11.00% / 13.00% Convertible Senior Secured Notes due 2028 – Biora Therapeutics, Inc., Guarantors, and GLAS Trust Company LLC
Indenture Agreements
PROGENITY, INC.
Biotechnology
NY
2023
Second Supplemental Indenture to 3.50% Convertible Senior Secured Notes Due 2026 – Intercept Pharmaceuticals, Inc. and U.S. Bank Trust Company, N.A.
Indenture Agreements
INTERCEPT PHARMACEUTICALS, INC.
Biotechnology
NY
2023
Third Supplemental Indenture to Senior Debt Securities Indenture between Intercept Pharmaceuticals, Inc. and U.S. Bank Trust Company, N.A.
Indenture Agreements
INTERCEPT PHARMACEUTICALS, INC.
Biotechnology
NY
2023
Ninth Supplemental Indenture to Indenture Dated March 30, 2011 between Gilead Sciences, Inc. and Computershare Trust Company, N.A.
Indenture Agreements
Gilead Sciences
Biotechnology
NY
2023
First Supplemental Indenture to Indenture for Convertible Senior Secured Notes between Invitae Corporation, Guarantors, and U.S. Bank Trust Company (August 22, 2023)
Indenture Agreements
Invitae Corp
Biotechnology
NY
2023
Indenture for 1.75% Convertible Senior Notes due 2028 between Ionis Pharmaceuticals, Inc. and U.S. Bank Trust Company, N.A.
Indenture Agreements
IONIS PHARMACEUTICALS INC
Biotechnology
DE
2023
Indenture for 4.00% Convertible Senior Notes due 2029 between Mirum Pharmaceuticals, Inc. and U.S. Bank Trust Company, N.A.
Indenture Agreements
Mirum Pharmaceuticals, Inc.
Biotechnology
DE
2023
Indenture for 4.5% Series A and B Convertible Senior Secured Notes due 2028 – Invitae Corporation, Guarantors, and U.S. Bank Trust Company
Indenture Agreements
Invitae Corp
Biotechnology
NY
2023
Officer’s Certificate of Amgen Inc. Relating to Issuance of Senior Notes (March 2023)
Indenture Agreements
Amgen Inc.
Biotechnology
NY
2023
Indenture for 4.5% Series A and B Convertible Senior Secured Notes due 2028 – Invitae Corporation, Guarantors, and U.S. Bank Trust Company
Indenture Agreements
Invitae Corp
Biotechnology
NY
2023
Fourth Supplemental Indenture to 2.0% Convertible Senior Notes Due 2030 between Exact Sciences Corporation and U.S. Bank Trust Company, N.A.
Indenture Agreements
EXACT SCIENCES CORP
Biotechnology
DE
2023
Novavax, Inc. and The Bank of New York Mellon Trust Company, N.A. Indenture for 5.00% Convertible Senior Notes Due 2027
Indenture Agreements
NOVAVAX INC
Biotechnology
NY
2022
Indenture for 1.00% Convertible Senior Notes due 2027 between Alnylam Pharmaceuticals, Inc. and The Bank of New York Mellon
Indenture Agreements
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
NY
2022
First Supplemental Indenture to 1.875% Convertible Senior Notes Due 2028 between Global Blood Therapeutics, Inc. and U.S. Bank Trust Company, N.A.
Indenture Agreements
Global Blood Therapeutics, Inc.
Biotechnology
2022
Indenture for 1.250% Convertible Senior Notes due 2027 between Sarepta Therapeutics, Inc. and U.S. Bank Trust Company, N.A.
Indenture Agreements
Sarepta Therapeutics, Inc.
Biotechnology
DE
2022
Indenture for 1.00% Convertible Senior Notes due 2027 between Alnylam Pharmaceuticals, Inc. and The Bank of New York Mellon
Indenture Agreements
ALNYLAM PHARMACEUTICALS, INC.
Biotechnology
NY
2022
Amgen Inc. Officer’s Certificate Relating to Issuance of Senior Notes Due 2029, 2033, and 2053
Indenture Agreements
Amgen Inc.
Biotechnology
NY
2022
Indenture for 1.00% Convertible Senior Notes due 2028 between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A.
Indenture Agreements
HALOZYME THERAPEUTICS INC
Biotechnology
NY
2022
Indenture for 2.50% Convertible Senior Notes due 2027 between Cerevel Therapeutics Holdings, Inc. and U.S. Bank Trust Company, N.A.
Indenture Agreements
ARYA Sciences Acquisition Corp II
Biotechnology
DE
2022
Second Supplemental Indenture to 3.00% Convertible Senior Notes due 2024 between Radius Health, Inc. and Wilmington Trust, N.A.
Indenture Agreements
Radius Health, Inc.
Biotechnology
NY
2022
Indenture for 3.50% Convertible Senior Notes due 2027 between Cytokinetics, Incorporated and U.S. Bank Trust Company, N.A.
Indenture Agreements
Cytokinetics, Incorporated
Biotechnology
DE
2022